Custirsen + Docetaxel
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Sep 1, 2012 → Jul 1, 2017
NCT ID
NCT01630733About Custirsen + Docetaxel
Custirsen + Docetaxel is a phase 3 stage product being developed by Achieve Life Sciences for Non-Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT01630733. Target conditions include Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01630733 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Non-Small Cell Lung Cancer